Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: Determination by kinetic PCR in formalin-fixed paraffin-embedded tissue

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1229-1239

  Darb Esfahani, Silvia ^a   Wirtz, Ralph M ^b   Sinn, Bruno V ^a   Budczies, Jan ^a   Noske, Aurelia ^a   Weichert, Wilko ^a   Faggad, Areeg ^a   Scharff, Susanne ^b   Sehouli, Jalid ^a   Oskay Özcelik, Guelten ^a   Zamagni, Claudio ^c   De Iaco, Pierandrea ^d   Martoni, Andrea ^c   Dietel, Manfred ^a   Denkert, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SIEMENS AG   (Germany)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PLATINUM COMPLEX;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RNA EXTRACTION; TUMOR VOLUME;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 72549115488     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0338     Document Type: Article

References (49)

1. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D et al. 1993 Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. Journal of Clinical Oncology 11 1957-1968. (Pubitemid 23304622)
2. Bardin A, Boulle N, Lazennec G, Vignon F & Pujol P 2004 Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer 11 537-551. (Pubitemid 39331282)
3. Bookman MA 2006 GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-lipososomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma. Journal of Clinical Oncology 24 256.
4. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A & Smyth JF 2002 Clin CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Cancer Research 8 2233-2239. (Pubitemid 34753595)
5. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN & Ngan HY 2008 Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstetrics and Gynecology 111 144-151.
6. Chang JC, Makris A, Gutierrez MC, Hilsenbeck SG, Hackett JR, Jeong J, Liu ML, Baker J, Clark-Langone K, Baehner FL et al. 2008 Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Research and Treatment 108 233-240.
7. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA & Hankinson SE 2007 A prospective study of postmenopausal hormone use and ovarian cancer risk. British Journal of Cancer 96 151-156. (Pubitemid 46094654)
8. Ercoli A, Scambia G, De Vincenzo R, Alimonti A, Petrucci F, Fattorossi A, Isola G, Benedetti Panici P, Caroli S & Mancuso S 1996 Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanism. Cancer Letters 108 7-14. (Pubitemid 26393554)
9. Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, Sayre J, Zhang L, Zaghi J, Dejbakhsh S et al. 2007 Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. PNAS 104 12849-12854.
10. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Escher G, Lippman M, Savlov E, Wittliff J et al. 1983 Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. Journal of Clinical Oncology 1 227-241. (Pubitemid 14189661)
11. Fujimoto J, Hirose R, Sakaguchi H & Tamaya T 2000 Clinical significance of expression of estrogen receptor alpha and beta mRNAs in ovarian cancers. Oncology 58 334-341. (Pubitemid 30265344)
12. Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA & Hamilton TC 1992 Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. Journal of the National Cancer Institute 15 592-601.
13. Harries M & Gore M 2002 Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncology 3 529-536. (Pubitemid 34993640)
14. Harvey JM, Clark GM, Osborne CK & Allred DC 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology 17 1474-1481.
15. Hatch KD, Beecham JB, Blessing JA & Creasman WT 1991 Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68 269-271.
16. Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ & Kjaer SK 2007 Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncology Reports 18 1051-1059.
17. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Jänicke F et al. 2007 Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics 39 655-660. (Pubitemid 46676104)
18. Hornung R, Urs E, Serenella E, Edward W, Ursula S, Urs H & Daniel F 2004 Analysis of potential prognostic factors in 111 patients with ovarian cancer. Cancer Letters 206 97-106. (Pubitemid 38281259)
19. Isola J, Kallioniemi OP, Korte JM, Wahlström T, Aine R, Helle M & Helin H 1990 Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. Journal of Pathology 162 295-301.
20. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H et al. 2005 ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 455-462.
21. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T & Thun MJ 2008 Cancer statistics 2008. CA: A Cancer Journal for Clinicians 58 71-96.
22. Karagol H, Saip P, Uygun K, Caloglu M, Eralp Y, Tas F, Aydiner A & Topuz E 2007 The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Medical Oncology 24 39-43.
23. Katabuchi H & Okamura H 2003 Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis. Medical Electron Microscopy 36 74-86. (Pubitemid 36898472)
24. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A et al. 2008 Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Medicine 5 e232.
25. Kommoss F, Pfisterer J, Thome M, Schäfer W, Sauerbrei W & Pfleiderer A 1992 Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecologic Oncology 47 317-322. (Pubitemid 23011411)
26. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A & Schairer C 2002 Menopausal hormone replacement therapy and risk of ovarian cancer. Journal of the American Medical Association 288 334-341. (Pubitemid 34761612)
27. Lacey JV Jr, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A & Hartge P 2006 Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. Journal of the National Cancer Institute 98 1397-1405. (Pubitemid 44530716)
28. Langdon SP, Hawkes MM, Lawrie SS, Hawkins RA, Tesdale AL, Crew AJ, Miller WR & Smyth JF 1990 Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. British Journal of Cancer 62 213-216. (Pubitemid 20242438)
29. Langdon SP, Crew AJ, Ritchie AA, Muir M, Wakeling A, Smyth JF & Miller WR 1994 Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. European Journal of Cancer 30A 682-686. (Pubitemid 24164260)
30. Lau KM, Mok SC & Ho SM 1999 Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. PNAS 96 5722-5727.
31. Lebeau A, Grob T, Holst F, Seyedi-Fazlollahi N, Moch H, Terracciano L, Turzynski A, Choschzick M, Sauter G & Simon R 2008 Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. Journal of Pathology 216 151-157.
32. Lee P, Rosen DG, Zhu C, Silva EG & Liu J 2005 Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecologic Oncology 96 671-677. (Pubitemid 40255486)
33. Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Risch HA, Puopolo M & Yu H 2006 The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clinical Cancer Research 12 1208-1214. (Pubitemid 43342510)
34. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W & Dubeshter B 1996 Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecologic Oncology 62 4-6. (Pubitemid 26234538)
35. McClay EF, Albright KD, Jones JA, Christen RD & Howell SB 1994 Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. British Journal of Cancer 70 449-452. (Pubitemid 24268546)
36. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA et al. 2002 Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 31 536-541. (Pubitemid 34130609)
37. Münstedt K, Steen J, Knauf AG, Buch T, von Georgi R & Franke FE 2000 Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 89 1783-1791. (Pubitemid 30794173)
38. Murdoch WJ 1996 Ovarian surface epithelium, ovulation and carcinogenesis. Proceedings of the Cambridge Philosophical Society. Biological Sciences 71 529-543.
39. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF & Langdon SP 2005 Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocrine-Related Cancer 12 851-866.
40. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351 2817-2826.
41. Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G et al. 2009 Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Research and Treatment 116 131-143.
42. Rodriguez C, Patel AV, Calle EE, Jacob EJ & Thun MJ 2001 Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. Journal of the American Medical Association 285 1460-1465. (Pubitemid 32221894)
43. Scambia G, Benedetti-Panici P, Ferrandina G, Distefano M, Salerno G, Romanini ME, Fagotti A & Mancuso S 1995 Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. British Journal of Cancer 72 361-366.
44. Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F & Silverberg SG 1998 Toward the development of a universal grading system for ovarian epithelial carcinoma. Gynecologic Oncology 70 2-12.
45. Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, Nafussi AA, Rye T, Rye R, StewartMet al. 2007 Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clinical Cancer Research 13 3617-3622.
46. Syed V, Zhang X, Lau KM, Cheng R, Mukherjee K & Ho SM 2005 Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene 24 8128-8143. (Pubitemid 41759812)
47. Tropé C, Marth C & Kaern J 2000 Tamoxifen in the treatment of recurrent ovarian carcinoma. European Journal of Cancer 36 S59-S61. (Pubitemid 30803658)
48. Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, Lück HJ, Sehouli J, Gropp M, Stähle A, Schmalfeldt B et al. 2007 AGO Ovarian Cancer Study Group. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy - a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecologic Oncology 105 132-137.
49. Winter WE III, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F & McGuire WP 2008 Gynecologic Oncology Group. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 26 83-89.